Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Jim Cramer recently endorsed Pfizer, excited by its cancer-fighting potential and robust drug pipeline. A caller praised ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

Pfizer Inc. (NYSE: PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Second, Pfizer's forward dividend yield stands at 7.47%. At first glance, the drugmaker's dividend payout ratio of 122.5% ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a Strong Buy despite market doubts.

Through the MoU, Pfizer and DoH are working jointly ... the MoU to foster long-term public-private partnerships that enhance Abu Dhabi’s global competitiveness in biomedical research, genomics ...